Slide 1: SomnoMed Investor Presentation Financial Year 2015-16
For personal use only SomnoMed Investor Presentation Financial Year 2015-16 ASX Investor Presentation | Page 0 Copyright ® and registered trademark notice
Slide 2: Disclaimer & Regulatory Disclosure
Disclaimer & Regulatory Disclosure For personal use only This document has been prepared as a summary only, and does not contain all information about the Company’s assets and liabilities, financial position and performance, profit and losses and the rights and liabilities attaching to the Company’s
Slide 3: Continuous strong growth in direct sales volumes drives 29% increase in MAS revenues
Continuous strong growth in direct sales volumes drives For personal use only 29% increase in MAS revenues Global unit sales growth Global revenue growth Units A$’000 70,000 50,000 $44.1m 58,983 60,000 51,355 40,000 50,000 $34.4m 43,438 $30.3m 40,000 35,841 30,000 30,878 30,000 $18.5m 20,000 $15.3m
Slide 4: Consistent strong quarterly growth in North America and Europe
Consistent strong quarterly growth in North America and Europe For personal use only North America Direct Europe APAC Quarterly unit sales Quarterly unit sales Quarterly unit sales 8,000 8,000 8,000 7,000 7,000 7,000 6,000 6,000 6,000 5,000 5,000 5,000 4,000 4,000 4,000 3,000 3,000 3,000 2,000 2,000
Slide 5: North America retains its share of global sales despite drop in sales through licensees
North America retains its share of global sales despite For personal use only drop in sales through licensees Total SomnoDent® devices sold 100% 90% 80% 41% 43% 46% 48% 50% 70% 60% North America direct 12% 11% North America licensee 50% 12% 5% 11% Europe 40% APAC 30% 36% 36% 37% 27% 31% 20% 10% 12%
Slide 6: Main Achievements in 2015/16
Main Achievements in 2015/16 o Direct global growth in volume accelerated in 2015/16, net average sales price improved, device GM improved, For personal use only underlying EBITDA increased by 141% o SomnoMed now operating in all important product market segments in the US. Quick adaptation in North
Slide 7: Finance: Summary Profit & Loss
Finance Summary Profit & Loss For personal use only Financial Summary – AUD $000’s 11/12 12/13 13/14 14/15 15/16* Total Group Revenue 15,246 18,489 30,274 34,438 44,084 28% MAS revenue 14,765 17,885 25,144 28,899 37,250 Managed Care revenue - 200 4,704 5,161 6,517 Other revenue 481 404 426 378 317 G
Slide 8: Underlying EBITDA grew by 141% year on year
Finance Underlying EBITDA grew by 141% year on year For personal use only A$m. 2,500 $2.1m. 2,000 SOM Underlying +141% 1,500 1,000 $0.87m. SOM Reported +70% 500 0 FY15 FY16 SOM reported SCA CEO recruitment/other Investor Presentation | Slide 7 Investor Presentation | Slide 7
Slide 9: Outlook and guidance for 2016/17 – strong continuing growth in core business and opening of first SCA centres
Group Outlook and guidance for 2016/17 – strong continuing For personal use only growth in core business and opening of first SCA centres o Global direct sales to grow by over 20%. North America licensee sales stabilising at low level o EBITDA of core business to grow by over 170% and by over 100% o
Slide 10: Outlook and guidance – SCA on its way
Outlook and guidance – SCA on its way For personal use only o Mr Jim Evanger appointed as CEO on 1 August 2016 o COO and Marketing Manager in process of being recruited o Roll out planning based on insurance reimbursements in different US states under way o First treatment centres to open in early 2
Slide 11: Outlook and 2016/17 guidance – strong performance of SomnoMed business will pay for start up cost of SCA
Outlook and 2016/17 guidance – strong performance of For personal use only SomnoMed business will pay for start up cost of SCA SomnoMed (Core) Volume (MAS units) +20% > 70,000 Group revenues +23% > $54m. EBITDA +100% $4m. SCA Centres operational 5 Patients treated > 1,000 Revenues > $2m. EBITDA ($4m
Slide 12: Contact details
For personal use only Contact details EXECUTIVE CHAIRMAN & CEO Dr. Peter Neustadt CHIEF FINANCIAL OFFICER Mr. Neil Verdal-Austin Address Level 3, 20 Clarke Street Crows Nest NSW 2065 Australia Telephone +61 (2) 9467 0400 Website www.somnomed.com.au Investor Presentation | Slide 11 Investor